Moderna Stock Today
| MRNA Stock | USD 108.85 0.96 0.89% |
Performance3 of 100
| Odds Of DistressLess than 8
|
Moderna is trading at 108.85 as of the 25th of April 2024, a 0.89% increase since the beginning of the trading day. The stock's open price was 107.89. Moderna has only a 8 % chance of going through financial distress over the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for Moderna are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of December 2018 | Category Healthcare | Classification Health Care |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. The company has 382.88 M outstanding shares of which 21.44 M shares are now shorted by private and institutional investors with about 5.26 trading days to cover. More on Moderna
Moderna Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Moderna's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Moderna or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Robert Moscato | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, NASDAQ Composite, NASDAQ Biotechnology, ARCA Biotechnology, Nasdaq 100, NASDAQ 100 Pre, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Moderna report their recommendations after researching Moderna's financial statements, talking to executives and customers, or listening in on Moderna's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Moderna. The Moderna consensus assessment is calculated by taking the average forecast from all of the analysts covering Moderna. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Moderna's financial statements, Moderna is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Moderna is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Moderna's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Moderna's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Moderna's financial leverage. It provides some insight into what part of Moderna's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Moderna (MRNA) is traded on NASDAQ Exchange in USA. It is located in 200 Technology Square, Cambridge, MA, United States, 02139 and employs 5,600 people. Moderna is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 41.31 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Moderna's market, we take the total number of its shares issued and multiply it by Moderna's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Moderna conducts business under Biotechnology sector and is part of Health Care industry. The entity has 382.88 M outstanding shares of which 21.44 M shares are now shorted by private and institutional investors with about 5.26 trading days to cover.
Moderna currently holds about 8.35 B in cash with (3.12 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.73.
Check Moderna Probability Of Bankruptcy
Ownership AllocationModerna maintains a total of 382.88 Million outstanding shares. The majority of Moderna outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Moderna to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Moderna. Please pay attention to any change in the institutional holdings of Moderna as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Moderna Ownership Details
Moderna Stock Price Odds Analysis
What are Moderna's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Moderna jumping above the current price in 90 days from now is about 10.07%. The Moderna probability density function shows the probability of Moderna stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.0224. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Moderna will likely underperform. Additionally, moderna has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Moderna to move above the current price in 90 days from now is about 10.07 (This Moderna probability density function shows the probability of Moderna Stock to fall within a particular range of prices over 90 days) .
Moderna Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Moderna that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Moderna's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Moderna's value.| Instituion | Recorded On | Shares | |
| Capital World Investors | 2023-12-31 | 3.6 M | |
| Manufacturers Life Insurance Co | 2023-12-31 | 3.5 M | |
| Norges Bank | 2023-12-31 | 3.5 M | |
| Coatue Management Llc | 2023-12-31 | 3.3 M | |
| Banque Pictet & Cie Sa | 2023-12-31 | 3.1 M | |
| Ubs Asset Mgmt Americas Inc | 2023-12-31 | 3 M | |
| Northern Trust Corp | 2023-12-31 | 3 M | |
| Amvescap Plc. | 2023-12-31 | 2.9 M | |
| Legal & General Group Plc | 2023-12-31 | 2.8 M | |
| Baillie Gifford & Co Limited. | 2023-12-31 | 45.7 M | |
| Vanguard Group Inc | 2023-12-31 | 33.9 M |
Moderna Historical Income Statement
Moderna Income Statement is one of the three primary financial statements used for reporting Moderna's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Moderna revenue and expense. Moderna Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Moderna's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 1.4 B, whereas Total Revenue is forecasted to decline to about 4.9 B. View More FundamentalsModerna Stock Against Markets
Picking the right benchmark for Moderna stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Moderna stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Moderna is critical whether you are bullish or bearish towards Moderna at a given time. Please also check how Moderna's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
Moderna Corporate Directors
Moderna corporate directors refer to members of a Moderna board of directors. The board of directors generally takes responsibility for the Moderna's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Moderna's board members must vote for the resolution. The Moderna board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Nancy Phelan | Director | Profile | |
| Philip Ranker | Director | Profile | |
| Joseph Ramelli | Independent Director | Profile | |
| Donald Williams | Independent Director | Profile |
How to buy Moderna Stock?
Before investing in Moderna, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Moderna. To buy Moderna stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Moderna. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Moderna stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Moderna stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Moderna stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Moderna, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Moderna Stock please use our How to Invest in Moderna guide.
Already Invested in Moderna?
The danger of trading Moderna is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Moderna is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Moderna. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Moderna is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (12.33) | Revenue Per Share 17.927 | Quarterly Revenue Growth (0.45) | Return On Assets (0.12) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.